Board of Directors

Mark Chandler, Ph.D. | Founding Director

Dr. Chandler founded Rules-Based Medicine, Inc. in 2002 and served as Chief Executive Officer and Chairman of the Board until his departure in 2004. Before heading Rules-Based Medicine, Dr. Chandler founded Luminex in May 1995, serving as Chairman of the Board and Chief Executive Officer. In 1982, he founded Inland Laboratories, Inc., which provides plant and bacterial toxins to the medical research community. As the President and CEO of Inland, Dr. Chandler received the KPMG Peat Marwick, High Technology Entrepreneur of the Year award in 1987. He received his Ph.D. in Immunology from the University of Texas Southwestern Medical School in Dallas in 1981. He is a fellow of the Explorers Club and serves on the Board of the EastWest Institute. Dr. Chandler is currently Chairman and CEO for Biophysical Corporation.



T. Craig Benson | President & CEO

Craig Benson joined Rules-Based Medicine, Inc. in January 2002 to direct its spin-off from Luminex Corporation. Until 2004, Benson also served as Chairman of the Board for Equity Resource Partners, LLC, a private investment company. From 1987 through September 2000, he was employed by Service Corporation International (NYSE: SCI), the world leader in death care-related services. During his tenure with SCI, he held various senior executive management positions, which included domestic and international merger and acquisition responsibilities, Vice-President of Marketing and Corporate Alliances, as well as President of SCI International, Ltd., SCI's International holding company. From 1990 to 1994, Benson served as President of Investment Capital Corporation, the private equity arm of SCI, which held over $350 million in assets. From 1984 to 1987, he held management positions with Pulaski Investment Corporation, a private holding company engaged in commercial and mortgage banking activities. Benson has served on the Board of Directors of various publicly held entities, including Florafax International, Tanknology Environmental, Inc., Equity Corporation International and Pinnacle Global Group, Inc. He received a BBA degree from Southern Methodist University in 1984.



Matthew Zell | Board Member

Mr. Zell is a Managing Director of Equity Group Investments (EGI). He also serves on the Board of Directors for Anixter International Inc, the world’s leading distributor of communication products, electrical and electronic wire cable and a leading distributor of fasteners and other small parts, and for Mexican Homebuilder Desarrolladora Homex, S.A. de C.V. Previously, Mr. Zell served on the board of GP Strategies Corp., a technology workforce training company. In addition to his board roles, Matthew has overseen a portfolio of investments in companies around the world. These include investments in distressed debt, and management of financial workouts for several companies, including the worldwide data center company Exodus Communications. Prior to joining EGI in 2001, Mr. Zell founded Prometheus Technologies, a provider of IT network engineering and user support goods and services, which he lead as President from 1990-2001. Mr. Zell has a B.S. in Aeronautical and Astronautical Engineering from the University of Illinois in Champaign.



Mark J. Gainor | Board Member

Mark has over 35 years of experience in developing and operating healthcare companies, commercializing new products on a global basis and sourcing and investing in innovative healthcare technologies. Mark and his father co-founded Gainor Medical, an international diabetic and medical supply and distribution company which was acquired by Matria Healthcare in 1999. He was an early investor and board member of Therasense, a healthcare technology company, which went public in 2001 and was acquired by Abbott Laboratories in 2004 and Venetec, which was sold to C.R. Bard in 2005. In addition, he was an early investor, board member and interim CEO for Adams Respiratory, a pharmaceutical company which went public and was subsequently acquired by Reckitt Benckiser in 2008. Mark currently serves as Chairman and CEO of Lucor Holdings, LLC, a private venture capital investment company investing primarily in health care technology and financial services companies. He serves on the Boards of Endovascular Research, an early stage stent technology company and Mark One Financial, a financial services firm. Mark graduated from the University of Alberta, Canada with a degree in Business Administration and Commerce.



David L. Schultz | Director

Mr. Schultz has served as a member of our board of directors since January 2010. Mr. Schultz is the President and Director of Sonic Healthcare USA, Inc., the U.S. division of Sonic Healthcare Limited, the worldís third largest diagnostic services company. From 1989 to 2005 Schultz served as the founder, Chief Executive Officer, and director of Clinical Pathology Laboratories, Inc., (CPL), an Austin, Texas clinical diagnostic service laboratory. Mr. Schultz currently holds advisory positions with the board of directors of Critical Connections, Inc. and the board of directors of Respiratory Research, Inc. Mr. Schultz was previously on the Board of Applied Genetics, which was later sold to Esoterix, Inc. Mr. Schultz received his Bachelor of Science in Business and Public Administration from The University of TexasóDallas in 1991. Mr. Schultz was selected to serve as a director due to his qualifications and leadership skills in the clinical diagnostics industry. Through his experience as President and Director of the worldís third largest diagnostic services company, Mr. Schultz has thorough knowledge of operations, logistics, processing, and global distribution of clinical diagnostic products and services, including expertise in physician sales, reimbursement, laboratory instrumentation and associated technology. Mr. Schultz also has extensive experience in regard to mergers and acquisitions in the clinical diagnostics industry.



Mark C. Capone | Director

Mr. Capone has served as a member of our board of directors since January 2010. Mr. Capone currently serves as President and Chief Operating Officer of Myriad Genetics Laboratories, Inc., or Myriad. From 2002 to 2006, he served as Senior Vice President of Sales of Myriad. Prior to joining Myriad, Mr. Capone served 17 years with Eli Lilly and Company, or Eli Lilly, where he held positions as Product Development Manager, Manufacturing Plant Manager and Area Sales Director. Many of these positions included responsibilities for Eli Lillyís neuro-psychiatric products. Mr. Capone received his bachelor of science degree in Chemical Engineering from Pennsylvania State University graduating with highest distinction in 1984, his Master of Science degrees in Chemical Engineering and Management from Massachusetts Institute of Technology in 1991. Mr. Capone was selected to serve as a director due to his knowledge and experience in the international distribution, logistics and marketing of clinical diagnostic products and services. Mr. Capone has been involved in the development and management of corporate strategies in clinical diagnostic operations, business processes and reimbursement matters, all of which will be of benefit to our company. In addition, he has commercial leadership and management experience in the neuro-psychiatric market which we believe will be valuable to the development of our molecular diagnostic tests.



Douglas H. Martin | Board Observer

Mr. Martin is an Executive Vice President of Stephens Group, Inc. and Stephens Inc., where he has been employed since 1981. At Stephens his responsibilities include the investment of the firm’s capital in private companies. Prior to joining Stephens he was employed in the mergers and acquisitions department of Morgan Stanley & Co. Incorporated. He received his B.A. degree, summa cum laude, in physics and economics from Vanderbilt University in 1975 and his M.B.A. from Stanford University in 1978. He serves as a member of the Board of Directors of numerous privately held companies. He was born and raised in Little Rock, Arkansas.



William G. Bock | Director Nominee

Mr. Bock currently serves as Senior Vice President of Finance and Administration and Chief Financial Officer of Silicon Laboratories, Inc. From 1997 to 1999, Mr. Bock served as President and Chief Executive Officer of DAZEL Corporation, a provider of electronic information delivery systems. After DAZELís acquisition by Hewlett-Packard, Mr. Bock then served as Vice President until 2001. Mr. Bock has also served as Executive Vice President and Chief Operating Officer of Tivoli Systems, which he helped take public in 1995 and was later acquired by IBM. Prior to joining Tivoli, Mr. Bock successfully completed an IPO at Convex Computer Corporation as CFO in 1986 and then became the Senior Vice President of Sales in 1991. Prior to Convex, Mr. Bock spent nine years in various finance roles at Texas Instruments including the Vice President and Controller of the Data Systems Group. Mr. Bock holds a B.S. degree in computer science from Iowa State University and a M.S. degree in industrial administration from Carnegie Mellon University. Mr. Bock was selected to serve as a director due to his credentials and qualifications in the area of public and financial accounting. Mr. Bock has particular skills in corporate finance, corporate governance, compliance, disclosure and compensation matters and has extensive experience in capital market transactions.